Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Sequential human immunodeficiency virus type 1 (HIV-1) isolates were obtained over a 29-month period from a person before, during, and after AZT therapy. DNA sequence analysis of polymerase chain-amplified reverse-transcriptase gene showed a gradual accumulation of mutations to peak resistance (IC50 2.13 microM AZT) in association with mutations at codons 44, 210, and 369, as well as at 41, 67, 70, and 215. Eight months after cessation of AZT therapy, when an HIV-1 isolate from the patient was again sensitive to AZT, these mutations had all returned to the pretherapy sequence.
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2022 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
